PARP inhibitor

Phase 2Small molecule

HHellenic Cooperative Oncology Group

PARP inhibitor is one of 145 small molecule programs targeting Myelodysplastic Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

144

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromeActive, not recruiting

Breast CancerRecruiting

Prostate CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Salivary Gland CarcinomaActive, not recruiting

Myelodysplastic SyndromePreclinical

Active, not recruiting

Breast CancerPhase 2

Recruiting

Prostate CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Salivary Gland CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

PARP inhibitor

HHellenic Cooperative Oncology Group

Phase 2

1 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Megace

Bristol-Myers Squibb

Preclinical

4 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 8

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 9

Tricor

JJagotec

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Ovarian Cancer

NCT05200260

Q4 2027

Phase 2Recruiting

Breast Cancer

NCT07117630

Q3 2028

Phase 2Recruiting

Salivary Gland Carcinoma

NCT06145308

Q2 2030

Phase 2Recruiting

Prostate Cancer

NCT05406999

Clinical

Trials by Indication[1]

Ovarian Cancer5 trials

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Unknown status·HHellenic Cooperative Oncology Group··NCT04724031·150 enrolled

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Unknown status·XXiaoxiang Chen··NCT05044091·100 enrolled

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

Unknown status·XXiaoxiang Chen··NCT04582552·60 enrolled

Show 2 more trials

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Recruiting·SShanghai Gynecologic Oncology Group·Phase 2·NCT05200260·220 enrolled

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Recruiting·NN.N. Alexandrov National Cancer Centre·Phase 2/3·NCT07472140·120 enrolled

PARP Inhibitor1 trial

Completed·UUniversity Hospital, Caen··NCT04774627·200 enrolled

Maintenance Therapy1 trial

PD1 and PARP for Maintenance Therapy in NSLLC

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05392686·52 enrolled

Myelodysplastic Syndrome1 trial

Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)

Completed·UUniversity Hospital, Caen··NCT04326023·178 enrolled

Prostate Cancer1 trial

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05406999·900 enrolled

2 more indications

Salivary Gland Carcinoma1 trial

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting·PPeking Union Medical College·Phase 2·NCT06145308·39 enrolled

Breast Cancer1 trial

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Recruiting·FFudan University·Phase 2·NCT07117630·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for PARP inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PARP inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PARP inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hellenic Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHellenic Cooperative Oncology Group

PARP inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q3 2028

Q2 2030

Trials by Indication[1]

Ovarian Cancer5 trials

PARP Inhibitor1 trial

Maintenance Therapy1 trial

Myelodysplastic Syndrome1 trial

Prostate Cancer1 trial

Salivary Gland Carcinoma1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News